Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2025
Effect of albumin infusion in patients with predicted severe acute pancreatitis: A randomized controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shu Wenqing, Wan Jianhua, Xu Huiting, Liu Fen, Zeng Zhengguo, Zhu Yin, Lu Nonghua, Xia Liang
Аннотация
BACKGROUND: Although previous studies have shown the potential advantages of albumin administration in critically ill patients, it has not been tested in patients with severe acute pancreatitis.
METHODS: In this single-center trial, we randomly assigned 60 patients with acute pancreatitis in the intensive care unit (ICU) to receive 5 % albumin and crystalloid solution or crystalloid solution alone. Patients in the albumin group received 30 g of 5 % albumin daily within the first 3 days of admission. The primary endpoint was remission of SIRS on Day 3 and the co-primary outcome was all-cause mortality 60 days after discharge.
RESULTS: No significant differences in patient characteristics, time of admission, degree of organ failure at admission, vital signs, biochemical indicators or total daily amount of administered fluid (P > 0.05) were detected between the two groups. There were also no significant differences between the patients in the crystalloid group and those in the albumin group regarding SIRS remission and 60-day mortality. However, the incidence of sepsis in the albumin group was lower than that in the crystalloid group (10 % vs. 36.7 %, respectively; P = 0.01).
CONCLUSION: In our study, albumin replacement did not reduce the remission rate of SIRS or the rate of mortality at 60 days in patients with acute pancreatitis.
METHODS: In this single-center trial, we randomly assigned 60 patients with acute pancreatitis in the intensive care unit (ICU) to receive 5 % albumin and crystalloid solution or crystalloid solution alone. Patients in the albumin group received 30 g of 5 % albumin daily within the first 3 days of admission. The primary endpoint was remission of SIRS on Day 3 and the co-primary outcome was all-cause mortality 60 days after discharge.
RESULTS: No significant differences in patient characteristics, time of admission, degree of organ failure at admission, vital signs, biochemical indicators or total daily amount of administered fluid (P > 0.05) were detected between the two groups. There were also no significant differences between the patients in the crystalloid group and those in the albumin group regarding SIRS remission and 60-day mortality. However, the incidence of sepsis in the albumin group was lower than that in the crystalloid group (10 % vs. 36.7 %, respectively; P = 0.01).
CONCLUSION: In our study, albumin replacement did not reduce the remission rate of SIRS or the rate of mortality at 60 days in patients with acute pancreatitis.